Cargando…

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial

BACKGROUND: Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). METHODS: Subjects with IPF and preserved forced vital capacity (FVC) were randomised to receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noth, Imre, Cottin, Vincent, Chaudhuri, Nazia, Corte, Tamera J., Johannson, Kerri A., Wijsenbeek, Marlies, Jouneau, Stephane, Michael, Andreas, Quaresma, Manuel, Rohr, Klaus B., Russell, Anne-Marie, Stowasser, Susanne, Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264778/ https://www.ncbi.nlm.nih.gov/pubmed/33419890 http://dx.doi.org/10.1183/13993003.01518-2020

Ejemplares similares

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
por: Noth, Imre, et al.
Publicado: (2019)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
por: Jouneau, Stéphane, et al.
Publicado: (2020)

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
por: Nakshbandi, Gizal, et al.
Publicado: (2021)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry
por: Moor, Catharina C., et al.
Publicado: (2020)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Feasibility of online home spirometry in systemic sclerosis–associated interstitial lung disease: a pilot study
por: Moor, Catharina C, et al.
Publicado: (2020)

Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-enabled Spirometer Is
por: Johannson, Kerri A.
Publicado: (2020)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Models of disease behavior in idiopathic pulmonary fibrosis
por: Johannson, Kerri A., et al.
Publicado: (2015)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Fibrosing interstitial lung diseases: knowns and unknowns
por: Cottin, Vincent, et al.
Publicado: (2019)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers
por: Moor, C. C., et al.
Publicado: (2018)

PAciFy Cough—a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough
por: Wu, Zhe, et al.
Publicado: (2022)

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Idiopathic Pulmonary Fibrosis Genetic Risk Factors, Function, and Mechanisms? The Concepts Are Starting to Gel
por: Bonham, Catherine A., et al.
Publicado: (2022)

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON
por: Song, Jin Woo, et al.
Publicado: (2019)

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
por: Maher, Toby M., et al.
Publicado: (2017)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)
por: Behr, Jürgen, et al.
Publicado: (2019)

Content Analysis of Idiopathic Pulmonary Fibrosis-related Information on Twitter
por: Ong, Shaun, et al.
Publicado: (2022)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement
por: Aronson, Kerri I., et al.
Publicado: (2021)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

Importance of Occupational Exposure Data: A National Idiopathic Pulmonary Fibrosis Registry Perspective
por: Teoh, Alan K. Y., et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vgiqjpnpsd1l7j9kamhftq8vjj